Safety of IL-17 and IL-23 inhibitors as treatment for immune mediated inflammatory diseases at conception and during pregnancy: an ENTIS study. (SAFE-PPREG)

Study identification

• EU PAS number:
  EUPAS1000000960
• Study ID:
  1000000960
• Official title and acronym:
  Safety of IL-17 and IL-23 inhibitors as treatment for immune mediated inflammatory diseases at conception and during pregnancy: an ENTIS study. (SAFE-PPREG)
• DARWIN EU® study:
  No
• Study countries:
  Belgium

  France

  Germany

  Ireland

  Israel

  Italy

  Netherlands

  Switzerland

  United Kingdom
• Study description:
  No information provided.
• Study status:
  Ongoing

Study timelines

Date when funding contract was signed

Planned:01/05/2025

Actual:01/05/2025

Study start date

Planned:01/02/2026

Actual:16/03/2026

Data analysis start date

Planned:01/02/2026

Date of final study report

Planned:01/02/2026

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable